Table1.
Characteristic | APOE e4 carriersa (n=61) | APOE e4 non-carriers (n=171) | APOE e4 carrier status unknown (n=192) |
---|---|---|---|
Age at PD diagnosis | |||
<50 | 5 (8%) | 18 (11%) | 15 (8%) |
50-59 | 11 (18%) | 49 (29%) | 43 (22%) |
60-69 | 21 (34%) | 48 (28%) | 79 (41%) |
70-79 | 17 (28%) | 45 (26%) | 44 (23%) |
80+ | 7 (12%) | 11 (6%) | 11 (6%) |
Age at initial visit | |||
<50 | 2 (3%) | 5 (3%) | 1 (1%) |
50-59 | 4 (7%) | 28 (16%) | 13 (7%) |
60-69 | 16 (26%) | 51 (30%) | 76 (39%) |
70-79 | 29 (48%) | 60 (35%) | 75 (39%) |
80+ | 10 (16%) | 27 (16%) | 27 (14%) |
Years between visit and diagnosis | |||
<5 | 28 (46%) | 74 (43%) | 74 (39%) |
5+ | 33 (54%) | 97 (57%) | 118 (61%) |
Sex | |||
Male | 48 (79%) | 124 (73%) | 145 (76%) |
Female | 13 (21%) | 47 (26%) | 47 (24%) |
Years of education | |||
High school only | 10 (16%) | 35 (21%) | 41 (21%) |
1-4 years of college | 33 (54%) | 84 (49%) | 82 (43%) |
Some graduate school | 18 (30%) | 52 (30%) | 69 (36%) |
Race | |||
White | 59 (96%) | 163 (95%) | 180 (94%) |
Black | 1 (2%) | 4 (2%) | 9 (4%) |
Asian | 1 (2%) | 2 (1%) | 2 (1%) |
Multiracial | 0 (0%) | 2 (1%) | 1 (1%) |
Reason for participation | |||
Participate in research study | 57 (93%) | 148 (87%) | 174 (91%) |
Clinical evaluation | 4 (7%) | 23 (13%) | 18 (9%) |
First predominant motor symptomb | |||
Gait disorder | 10 (20%) | 24 (21%) | 37 (23%) |
Falls | 0 (0%) | 0 (0%) | 6 (4%) |
Tremor | 20 (39%) | 51 (45%) | 66 (40%) |
Slowness | 21 (41%) | 38 (34%) | 54 (33%) |
Family history of dementiac | |||
No | 34 (56%) | 100 (59%) | 119 (63%) |
Yes | 27 (44%) | 70 (41%) | 70 (37%) |
Antipsychotic medication used | |||
No | 153 (89%) | 51 (84%) | 166 (86%) |
Yes | 18 (11%) | 10 (16%) | 25 (13%) |
Dopaminergic agonist use | |||
No | 36 (59%) | 98 (57%) | 111 (58%) |
Yes | 25 (41%) | 73 (43%) | 81 (42%) |
Includes 7 APOE e4 homozygotes
10 APOE e4 carriers, 58 non-carriers, and 29 with e4 carrier status unknown were missing information on the first predominant motor symptom
1 APOE e4 non-carrier and 3 with unknown e4 carrier status were missing information on family history of dementia
1 subject with unknown APOE e4 carrier status was missing data on antipsychotic medication use